2.10
-0.20 (-8.70%)
| Previous Close | 2.30 |
| Open | 2.30 |
| Volume | 92,374 |
| Avg. Volume (3M) | 2,806,763 |
| Market Cap | 19,819,968 |
| Price / Book | 2.01 |
| 52 Weeks Range |
| Operating Margin (TTM) | -2,518.17% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | 56.80% |
| Total Debt/Equity (MRQ) | 25.43% |
| Current Ratio (MRQ) | 0.080 |
| Operating Cash Flow (TTM) | -1.07 M |
| Return on Assets (TTM) | -8.04% |
| Return on Equity (TTM) | -21.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Gelteq Limited | - | - |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.50 |
|
Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 60.36% |
| % Held by Institutions | 1.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Wedbush Securities Inc | 31 Mar 2025 | 52,250 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Jun 2025 | Announcement | Gelteq Expands U.S. Operations with Healthy Extracts Inc. as North American Fulfillment Partner |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |